[{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"Sun Yat-sen University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deulorlatinib","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shenzhen TargetRx \/ Sun Yat-sen University","highestDevelopmentStatusID":"10","companyTruncated":"Shenzhen TargetRx \/ Sun Yat-sen University"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"Sun Yat-sen University | Tongji Hospital | Sichuan Cancer Hospital | The First Affiliated Hospital of Zhengzhou University | West China Hospital | Zhejiang University | Jilin Provincial Tumor Hospital | Hunan Cancer Hospital | Shandong Cancer Hospital and","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deulorlatinib","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shenzhen TargetRx \/ Sun Yat-sen University | Tongji Hospital | Sichuan Cancer Hospital | The First Affiliated Hospital of Zhengzhou University | West China Hospital | Zhejiang University | Jilin Provincial Tumor Hospital | Hunan Cancer Hospital | Shandong Cancer Hospital and","highestDevelopmentStatusID":"10","companyTruncated":"Shenzhen TargetRx \/ Sun Yat-sen University | Tongji Hospital | Sichuan Cancer Hospital | The First Affiliated Hospital of Zhengzhou University | West China Hospital | Zhejiang University | Jilin Provincial Tumor Hospital | Hunan Cancer Hospital | Shandong Cancer Hospital and"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"Sun Yat-sen University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deulorlatinib","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shenzhen TargetRx \/ Sun Yat-sen University","highestDevelopmentStatusID":"10","companyTruncated":"Shenzhen TargetRx \/ Sun Yat-sen University"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"The First Affiliated Hospital of Bengbu Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deulorlatinib","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shenzhen TargetRx \/ The First Affiliated Hospital of Bengbu Medical University","highestDevelopmentStatusID":"10","companyTruncated":"Shenzhen TargetRx \/ The First Affiliated Hospital of Bengbu Medical University"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"Simcere Zaiming","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Deulorlatinib","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Shenzhen TargetRx","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen TargetRx \/ Simcere Zaiming","highestDevelopmentStatusID":"10","companyTruncated":"Shenzhen TargetRx \/ Simcere Zaiming"}]